- « Previous
- Clinical Pharmacology
- Next »
Ceftin
Clinical Pharmacology
Ceftin
| CAE-516 and CAE-517* | CAEA4001 and CAEA4002† | |||
| 5 Day (n = 127) |
10 Day (n = 139) |
5 Day (n = 173) |
10 Day (n = 192) |
|
| Clinical success (cure + improvement) | 80% | 87% | 84% | 82% |
| Clinical cure | 61% | 70% | 73% | 72% |
| Clinical improvement | 19% | 17% | 11% | 10% |
| *95% Confidence interval around the success difference
[-0.164, +0.029]. †95% Confidence interval around the success difference [-0.061, +0.103]. |
||||
The response rates for patients who were both clinically and bacteriologically evaluable were consistent with those reported for the clinically evaluable patients.
Safety: In these clinical trials, 399 patients were treated with CEFTIN for 5 days and 402 patients with CEFTIN for 10 days. No difference in the occurrence of adverse events was observed between the 2 regimens.
REFERENCES
1.National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 3rd ed. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25. Villanova, Pa: NCCLS; 1993.
2.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. 4th ed. Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7. Villanova, Pa: NCCLS; 1990.
Generic Name: Cefuroxime Axetil
- « Previous
- Clinical Pharmacology
- Next »
Vaporizing the Signs of HPV
Vaporizing the Signs of HPV" />HPV is a common infection that often strikes women in their early 20's. Learn how one doctorSee more WebMD Videos »
Sex & Relationships
Get tips to boost your love life.
